tiprankstipranks
Advertisement
Advertisement

MNKD Stock Latest News

MannKind announces milestones in development of nintedanib DPI for IPF
The FlyMannKind announces milestones in development of nintedanib DPI for IPF
27d ago
MNKD
MannKind Gains FDA Approval for Afrezza Pediatric Use
PremiumCompany Announcements
MannKind Gains FDA Approval for Afrezza Pediatric Use
28d ago
8K
MNKD
MannKind price target raised to $11 from $10 at Wells Fargo
PremiumThe Fly
MannKind price target raised to $11 from $10 at Wells Fargo
29d ago
MNKD
MannKind announces FDA approval of Afrezza for use in children aged 6 and older
PremiumThe Fly
MannKind announces FDA approval of Afrezza for use in children aged 6 and older
1M ago
MNKD
MannKind Released From Major Afrezza Trial Obligation
PremiumCompany Announcements
MannKind Released From Major Afrezza Trial Obligation
1M ago
8K
MNKD
MannKind Shareholders Reaffirm Board, Pay, and Auditor Roles
PremiumCompany AnnouncementsMannKind Shareholders Reaffirm Board, Pay, and Auditor Roles
1M ago
8K
MNKD
MannKind Leans Into Growth Amid Earnings Volatility
Premium
Company Announcements
MannKind Leans Into Growth Amid Earnings Volatility
2M ago
MNKD
MannKind price target lowered to $7 from $8 at Mizuho
Premium
The Fly
MannKind price target lowered to $7 from $8 at Mizuho
2M ago
MNKD
MannKind price target raised to $10 from $8 at H.C. Wainwright
PremiumThe Fly
MannKind price target raised to $10 from $8 at H.C. Wainwright
2M ago
MNKD
MannKind price target raised to $10 from $8 at Wells Fargo
PremiumThe Fly
MannKind price target raised to $10 from $8 at Wells Fargo
2M ago
MNKD
MannKind reports Q1 EPS (2c), consensus 1c
PremiumThe Fly
MannKind reports Q1 EPS (2c), consensus 1c
2M ago
MNKD
MannKind Buy Rating Reiterated as United Therapeutics Expands DPI Partnership; $8 Price Target Unchanged
PremiumRatings
MannKind Buy Rating Reiterated as United Therapeutics Expands DPI Partnership; $8 Price Target Unchanged
2M ago
MNKD
MNKD Earnings this Week: How Will it Perform?
PremiumPre-EarningsMNKD Earnings this Week: How Will it Perform?
2M ago
MNKD
MannKind’s Inhaled Nintedanib Trial: Early IPF Study Moves Forward
Premium
Company Announcements
MannKind’s Inhaled Nintedanib Trial: Early IPF Study Moves Forward
2M ago
MNKD
MannKind price target lowered to $8 from $10 at Mizuho
Premium
The Fly
MannKind price target lowered to $8 from $10 at Mizuho
3M ago
MNKD
MannKind price target lowered to $6 from $7 at Truist
PremiumThe Fly
MannKind price target lowered to $6 from $7 at Truist
3M ago
MNKD
Theravance Biopharma price target raised to $17 from $14 at B. Riley
PremiumThe Fly
Theravance Biopharma price target raised to $17 from $14 at B. Riley
3M ago
MNKD
TBPH
MannKind price target lowered to $8 from $10 at Wedbush
PremiumThe Fly
MannKind price target lowered to $8 from $10 at Wedbush
4M ago
MNKD
UTHR
Biotech Bloodbath Drags Health Care Down as MannKind and Soleno Stocks Sink
PremiumMarket News
Biotech Bloodbath Drags Health Care Down as MannKind and Soleno Stocks Sink
4M ago
IBB
XBI
MannKind price target lowered to $7 from $8 at Wells Fargo
PremiumThe FlyMannKind price target lowered to $7 from $8 at Wells Fargo
4M ago
MNKD
MannKind price target lowered to $8 from $11 at H.C. Wainwright
Premium
The Fly
MannKind price target lowered to $8 from $11 at H.C. Wainwright
4M ago
MNKD
MannKind downgraded to Sector Perform from Outperform at RBC Capital
Premium
The Fly
MannKind downgraded to Sector Perform from Outperform at RBC Capital
4M ago
MNKD
UTHR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >